We further assessed the co-occurrence of KRASm isoforms and co-altered genes with implications for immunotherapy response including TMB ≥ 10 mutations/Mb, and PD-L1 expression in non-Sq NSCLC and Sq NSCLC for comparison. The gene discussed is CD274; the disease is non-small cell lung carcinoma.